Treatment initiation for parkinson's disease in Australia 2013-2018: a nation-wide study
Details
Publication Year 2022-06-03,Volume 22,Issue #1,Page 483
Journal Title
BMC Geriatrics
Abstract
BACKGROUND: Guidelines highlight the importance of an individualized approach to treatment initiation for Parkinson's disease. Our aim was to investigate initiation of anti-Parkinson medication in Australia from 2013-2018, and to determine factors predicting choice of initial treatment. METHODS: Cohort of new-users (N = 4,887) of anti-Parkinson medication aged ≥ 40 years were identified from a 10% random representative sample of national medication dispensing data from July-2013 to June-2018. Changes in treatment initiation were examined across the whole cohort and stratified by age and sex. RESULTS: Treatment initiation was most frequent with levodopa followed by non-ergot dopamine agonists (DAs) and anticholinergics. Two thirds initiated with levodopa across the study period. Initiation with non-ergot DAs increased from 22 to 27% (rate ratio, RR 1.23, 95% confidence interval, CI 1.02-1.47) and initiation with anticholinergics decreased from 6.9% to 2.4% (RR 0.34, 95% CI 0.21-0.55) from 2013-2018. Among persons aged ≥ 65 years, one third of women and one fourth of men initiated on levodopa. Among women aged < 65 years, rates of treatment initiation with DAs (37%) and levodopa (37%) were similar in 2013/2014 but initiation with DA exceeded levodopa thereafter. Among men aged < 65 years, treatment initiation with levodopa (44%-49%) remained more frequent than initiation with DAs (29%-32%) throughout the study period. CONCLUSIONS: Treatment initiation with levodopa was most frequent among persons aged ≥ 65 years, consistent with current guidelines. Whilst the value of levodopa sparing strategies is unclear, treatment initiation with DA has become increasingly common relative to levodopa among women but not among men aged < 65 years.
Publisher
BMC
Keywords
Adult; Aged; Antiparkinson Agents/therapeutic use; Cholinergic Antagonists/therapeutic use; Dopamine Agonists/therapeutic use; Female; Humans; *Levodopa/therapeutic use; Male; Middle Aged; *Parkinson Disease/diagnosis/drug therapy/epidemiology; *Antiparkinson drugs; *Australia; *Parkinson’s disease; *Pharmacoepidemiology; *Sex differences
WEHI Research Division(s)
Population Health And Immunity
PubMed ID
35658842
Open Access at Publisher's Site
https://doi.org/10.1186/s12877-022-03095-3
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2022-06-17 09:28:49
Last Modified: 2022-06-17 09:53:06
An error has occurred. This application may no longer respond until reloaded. Reload 🗙